NEW YORK (GenomeWeb News) – Epigenomics said today that it has completed the submission of its blood-based test for the detection of colorectal cancer for premarket approval by the US Food and Drug Administration.

The submission of the fourth and final module of its Epi proColon test last month included the results of a comparative, head-to-head study between this test and fecal immunochemical test screening, clinical validation study data, and other clinical study results that were generated during the test's development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.